Myomap is an investigational ultrasound contrast agent for assessment of myocardial perfusion and has been tested in animals to determine infarct volumes in cases of coronary artery occlusion. The deposit microbubbles of Myomap consist of air filled human serum albumin microcapsule with a thick and rigid shell.

From ESAOTE S.p.A.;
'The MyLab™30CV ultrasound system is an evolutionary step in ultrasound technology. Weighing less than 20 pounds, it is the first compact ultrasound system to deliver premium console performance. And with mobile, portable or stationary configurations, MyLab30CV can adapt to any clinical environment.'

From Medison Co.,Ltd.;
'Medison's MySono 201 brings the power and flexibility of digital imaging within the reach of everyone. Its lightweight and compact design, featuring 2D black-and-white imaging, a generous 640x480 resolution LCD display, and an extensive range of multifrequency transducers, offers versatility as well as high performance. An AC/DC power supply, outputs for connection to an external monitor, and attractive pricing make the MySono 201 perfect for private practitioners, smaller clinics, and educational facilities.'

(MCE) Myocardial contrast echocardiography is a contrast enhanced ultrasound method that utilizes intravenous injected microbubbles as red blood cell tracers. MCE can assess myocardial perfusion both at rest and stress to evaluate viable myocardium after acute infarction.
MCE perfusion imaging improves the blood echoes during the microbubble passage and the imaging system suppresses the clutter represented by non-contrast-bearing tissue.

See also Injection Rate, Stress Echocardiogram, and Myomap.

Bristol-Myers Squibb Medical Imaging, Inc. was a wholly-owned subsidiary of Bristol-Myers Squibb Company (NYSE: BMY), a pharmaceutical and related health care products company. Bristol-Myers Squibb sold its medical imaging business in 2007 to the private equity firm Avista Capital Partners for $525 million, as part of its effort to focus on its core pharmaceutical pipeline.
Formed in 1956 as New England Nuclear Corporation (NEN), the company grew to become a leader in the field of diagnostic imaging and later evolved through its transition from NEN to DuPont, followed by Bristol-Myers Squibb Medical Imaging (BMS), and finally named Lantheus Medical Imaging.